The company
The pioneer and inventor of cutting edge diagnostic devices that can non-invasively diagnose and assess the risk of diabetes and its complications.
Company
Established in 2003, Diagnoptics is the pioneer and inventor of cutting edge diagnostic devices that can non-invasively diagnose and assess the risk of diabetes and its complications. Its technological advance in detecting fluorescence of Advanced Glycation Endproducts (AGEs) has led to the invention of the AGE Reader – a state of art diagnostic device which can determine the tissue accumulation of AGEs in 12 seconds.
AGEs are essential biomarkers of metabolic and glycemic stress and have been implicated as causative factors in the progression of a host of age-related diseases, such as atherosclerosis, diabetes, renal failure and Alzheimer. The amount of AGEs in tissue serves as an important risk predictor of diabetes and its complications.
Mission
DiagnOptics is committed to the technological development and innovation in AGEs’ detection through continuous dedication on non-invasive biomedical technologies.
Our mission is to improve the standard of clinical diagnosis and risk assessment on diabetes and its complications.
History
| 1995 | Dr. Smit and his co-workers made a coincidental finding of increased autofluorescence of the skin in many diabetes patients when they were performing fluorescein capillary leakage studies in diabetes. |
| 1996 | Dr. Smit and Dr. Graaff developed dedicated prototypes to assess skin autofluorescence in human |
| 1998 | The first clinical studies in diabetes and renal failure were started with an advanced prototype of the AGE Reader in the University Hospital Groningen, the Netherlands |
| 1999 | Filed patent application for the AGE Reader and published the first scientific report on the clinical use of AGE Reader prototype in diabetic patients |
| 2000 | Initiated the first large scale follow-up study in the Zwolle region |
| 2003 | Dr. Smit and Dr. Graaff founded DiagnOptics in Groningen, the Netherlands |
| 2004 | The first clinical study on AGE Reader were published in Diabetologia |
| 2005 | AGE Reader was first shown to future users (EASD, Athens 2005) |
| 2006 | AGE Reader received CE approval for commercialization in Europe |
| 2009 | AGE Reader CU (Compact Unit) received CE approval |
| 2010 | DiagnOptics received ISO 13485 certification for its Quality Management System |
| 2011 | Diab-spot was first shown to future users (Prediabetes, Madrid 2011) |
| 2011 | Diab-spot received CE approval |
| 2012 | First demonstration of the AGE Reader mu at the EASD 2012 in Berlin |
| 2013 | AGE Reader mu received CE approval |
| 2014 | Installed base > 2000 units |
| 2015 | Ranked 33rd in Deloitte Technology Fast50 and sector winner Life Sciences |
Diagnoptics Management | The AGE Reader
Would you like to learn more about our products? Request any information you wish to receive here.
Our contact details
Diagnoptics Technologies B.V.
Aarhusweg 4-9
9723 JJ Groningen
The Netherlands
Tel: +31 (0)50 589 0612
Fax: +31 (0)50 589 0613
E-mail: info@diagnoptics.com
Follow us on Twitter
Follow us on LinkedIn
More information about Diagnoptics.
Information on Diagnoptics' products and Advanced Glycation Endproducts.
Information about Advanced Glycation Endproducts, the AGE measurement and clinical validation.